TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program

12 Mar 2019

Trace Histories is a purpose-built distributed ledger solution for ensuring patient safety by 2023 DSCSA deadline.

TraceLink has submitted its interoperable blockchain network solution for the FDA Pilot Project Program under the Drug Supply Chain Security Act (DSCSA). Built on TraceLink’s digital supply network, Trace Histories leverages distributed ledger technology and is designed specifically to help pharmaceutical manufacturers, wholesale distributors, pharmacies, and hospitals securely exchange information and satisfy the 2023 DSCSA requirement.

TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program

“The 275,000+ partners on our end-to-end digital supply network are already validated, which provides companies with a unique opportunity to leverage blockchain technology, while ensuring the safe exchange of data,” said Shabbir Dahod, president and CEO, TraceLink. “By combining our nearly two decades of expertise in standards-based compliance for track and trace in the pharmaceutical supply chain with our deep technical knowledge, we have created Trace Histories, a breakthrough blockchain solution. Trace Histories maintains the pseudonymity of blockchain participants and control of confidential information within each participant’s system by only enabling the disclosure of information necessary to respond to verified trace requests.”

With the unique advantage of leveraging TraceLink's end-to-end digital network and existing base of pre-verified customers and trade partners, Trace Histories is a distributed ledger network that integrates directly into companies’ existing global compliance and serialization infrastructures. The blockchain network solution employs a “gather upon request” approach with permissioned data security, allowing companies to securely share critical and confidential information with authorized partners in an open, interoperable format to meet the final 2023 DSCSA deadline requiring full unit level traceability across the supply chain. Trace Histories was designed from the ground up to be standardized and support interoperability across blockchain networks.

Other participants in TraceLink’s pilot project include pharmaceutical manufacturers, wholesale distributors, major retail pharmacy chains, diversified healthcare organizations, and third-party logistics providers. The pilot project will be guided and managed by TraceLink’s Blockchain Network Innovation Forum.

By 2023, members of the US supply chain will need to have processes and systems in place to meet the DSCSA requirement for an interoperable, electronic tracing of pharmaceutical products at the packaging level. Announced by the FDA last month, the DSCSA Pilot Project Program is a 2019 effort to explore technologies that will enhance the tracing and verification of pharmaceutical products in the US supply chain.

Read More

Related news

Specialist API CDMO acquired by GHO Capital

Specialist API CDMO acquired by GHO Capital

16 Mar 2019

Future plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.

Read more 
Bringing next generation single-use sensor technologies to the life science market

Bringing next generation single-use sensor technologies to the life science market

14 Mar 2019

Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.

Read more 
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

13 Mar 2019

Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

Read more 
Overcoming lyophilization challenges at Interphex 2019

Overcoming lyophilization challenges at Interphex 2019

10 Mar 2019

Line of Sight approach to freeze-drying enables organizations to bring pharmaceutical products safely and quickly to market.

Read more 
Catalent invests over $27 million to commercialize Zydis Ultra

Catalent invests over $27 million to commercialize Zydis Ultra

7 Mar 2019

Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT.

Read more 
Novel systems for membrane chromatography

Novel systems for membrane chromatography

6 Mar 2019

Optimally run membrane chromatography processes will provide higher productivity, smaller-scale operations and increased robustness.

Read more 
Lilly to introduce lower-priced insulin

Lilly to introduce lower-priced insulin

5 Mar 2019

Authorized generic version of Humalog will be available in US pharmacies at 50% lower list price.

Read more 
Biogen acquisition boosts its ophthalmology pipeline

Biogen acquisition boosts its ophthalmology pipeline

4 Mar 2019

Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.

Read more 
Uniqsis expands LED photoreactor range

Uniqsis expands LED photoreactor range

3 Mar 2019

The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.

Read more 
'Tamper-evident' benefits are evident

'Tamper-evident' benefits are evident

28 Feb 2019

2019 will mark Uniplast's debut at this year's edition of CPhI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.

Read more